Interview with Byoung Joo Gwag, CEO, President, Neurotech Pharmaceuticals
What was the vision behind the creation of Neurotech back in 1998, originally as a Research Center, and then as an independent bio-tech company? It all began in 1998 when…
Address: 4F Hyunwoo Building, Gomae- dong 381-1, Giheung-gu, Yongin -si, Gyeonggi-do446-901, Republic of Korea
Tel: 82-31-215-9985
Web: http://gntpharma.com/intro/
Established in 1998 Neurotech Pharmaceuticalshas received the G7 Project Award from the Ministry of Science & Technology:Development of Alzheimer’s Disease models and Neuroprotectant compounds.Neurotech team members are working diligently with shareholder support to develop the next generation of medicines.Neurotech has been developing Neu2000 and AAD-2004 over the last 8 years and has recently discovered two additional promising compounds. Neurotech has also expanded its drug development capabilities over this period. In preparing for competition in the global marketplace, Neurotech has secured sufficient cash flow for R&D Funding through public listing, employing a conservative business model, and establishing a new drug development infrastructure through the introduction of IT. Its partner, Eolith, is a company that specializes in Broadband Convergence Network technology. Neurotech is working with Eolith and large medical center to construct a Ubiquitous Health Monitoring System (UHMS) to select patients with stroke and Alzheimer’s and maximize the efficacy of drugs. Neurotech ultimately seeks to gain entry into the pharmaceutical industry through clinical studies and the marketing of new drugs.In 2008, Neurotech has successfully completed the Neu2000 clinical phase I study in the U.S.
What was the vision behind the creation of Neurotech back in 1998, originally as a Research Center, and then as an independent bio-tech company? It all began in 1998 when…
Dr Kyung Sook Kim, CEO of Corestem, explains how her company has been pioneering the Korean stem cell industry since its foundation in 2003. She also discusses reimbursement and regulation…
Dr Jino Park, founder and CEO of P&K Skin Research Centre, offers his assessment of the success of the Korean pharmaceutical industry, and the potential cosmetic products of the future.…
Ji-Young Lee, senior director clinical operations, and general management & business administration Korea of PAREXEL Korea discusses the strengths of Korea’s clinical research environment, and how PAREXEL can leverage its…
* This interview was conducted before GE’s announcement of its divestment of the GE Biopharma business Francis Van Parys, president & CEO of GE Healthcare Korea discusses their ambitions to…
Young Kim, founder and CEO of Synex Consulting Ltd., a consulting firm assisting healthcare companies in introducing and marketing their products on the Korean market, discusses how Synex’s ICC (In-Country…
Min-Young Kim, general manager at Ipsen Korea discusses her strategy to refocus the Korean affiliate away from the toxin market and towards oncology and rare diseases. She also documents Ipsen’s…
Woosok Lee, CEO of Kolon Pharma, Kolon Life Science and Kolon TissueGene, offers his insights into the potential of their blockbuster product Invossa which could exceed USD five billion of…
Dr Jin San-Yoo, president and CEO of PharmAbcine, lifts the lid on the company’s combination therapy with MSD’s blockbuster oncology treatment Keytruda. Dr Yoo explains the rationale behind his decision…
Professor Dae Ho Lee has been researching and treating Korean cancer patients for more than 20 years and advises the current government on healthcare policy. He breaks down the benefits…
This week the Korean Ministry of Food and Drug Safety announced that as of 12th March 2019 a revised narcotics bill will go into effect that will allow imports of medical…
Dr Byung Guk Yang, CEO of Daewoong Bio, explains the challenges the Korean healthcare system is facing and how his experience in the public sector now helps him lead a…
YJ Kim, country manager at BD Korea, discusses the integration of Bard into BD at the local level. He also offers his insights into the challenges of approval and pricing…
See our Cookie Privacy Policy Here
